BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 874.57M | 776.13M | 825.41M | 745.15M | 747.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 874.57M | 776.13M | 825.41M | 745.15M | 747.31M |
| Cost of Revenue | -573.02M | 549.56M | 311.40M | 310.29M | -437.54M |
| Gross Profit | 1.45B | 226.57M | 514.01M | 434.86M | 1.18B |
| SG&A Expenses | 324.16M | 268.42M | 232.28M | 206.12M | 266.61M |
| Depreciation & Amortization | 4.85M | 4.85M | 4.85M | 4.85M | 9.65M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 677.92M | 822.83M | 548.52M | 521.25M | 585.91M |
| Operating Income | 196.64M | -46.69M | 276.89M | 223.89M | 161.41M |
| Income Before Tax | -27.15M | -26.32M | 297.87M | 238.09M | 169.64M |
| Income Tax Expenses | 19.42M | 4.42M | 57.34M | 52.40M | 44.70M |
| Earnings from Continuing Operations | -46.57M | -30.74M | 240.53M | 185.69M | 124.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.57M | -30.74M | 240.53M | 185.69M | 124.94M |
| EBIT | 196.64M | -46.69M | 276.89M | 223.89M | 161.41M |
| EBITDA | 209.68M | -28.21M | 295.45M | 245.96M | 185.01M |
| EPS Basic | -0.24 | -0.16 | 1.25 | 0.97 | 0.66 |
| Normalized Basic EPS | 0.70 | -0.09 | 0.97 | 0.78 | 0.56 |
| EPS Diluted | -0.24 | -0.16 | 1.23 | 0.95 | 0.64 |
| Normalized Diluted EPS | 0.70 | -0.09 | 0.94 | 0.76 | 0.54 |
| Average Basic Shares Outstanding | 192.23M | 192.03M | 191.91M | 190.97M | 190.69M |
| Average Diluted Shares Outstanding | 192.23M | 192.03M | 197.09M | 196.47M | 196.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |